Article thumbnail
Location of Repository

Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations

By Hovav Nechushtan, Tamar Hamburger, Susan Mendelson, Luna Kadouri, Nir Sharon, Eli Pikarsky and Tamar Peretz
Topics: Research Article
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2004). A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell
  2. (1999). Clinical significance of apoptosis-related factors
  3. (2007). Dahiya R: MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res
  4. (2004). Dalla-Favera R: The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature
  5. (2006). et al.: MDM2 SNP309 accelerates tumor formation in a gender-specific and hormonedependent manner. Cancer Res
  6. (2001). Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood
  7. (2006). Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res
  8. (2007). Genotoxic stress regulates expression of the proto-oncogene
  9. (2006). Gilks CB: MDM2 protein expression is a negative prognostic marker in breast carcinoma. Mod Pathol
  10. (2005). GM: A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle
  11. (2006). Goto H: MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis.
  12. (2007). Haplotype structure and selection of the MDM2 oncogene in humans.
  13. (2007). Hemminki K: MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis
  14. (1995). LC: The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nature genetics
  15. (2007). M: MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling. Breast Cancer Res Treat
  16. (2005). Mdm2 in growth signaling and cancer. Growth Factors
  17. (1997). of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. American journal of human genetics
  18. (2000). Prognostic value of simultaneous expression of p21 and mdm2 in breast carcinomas treated by adjuvant chemotherapy with antracyclin. Oncol Rep
  19. (2004). Puricelli L: Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas.
  20. (2004). T: A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers.
  21. (1996). The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nature genetics
  22. (2006). The single nucleotide polymorphism IVS1+309 in mouse double minute 2 does not affect risk of familial breast cancer. Cancer Res
  23. (2007). Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells.
  24. (2004). Wahl GM: Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. Embo J

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.